Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BP-897 Bioprojet.

A Preti1

  • 1Genneruxi Medical Center, via Costantinopoli 42, I-09129, Cagliari, Italy. apreti@tin.it

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

BP-897, a dopamine D3 receptor agonist, shows promise in reducing drug craving and relapse. Preclinical studies indicate it inhibits cue-induced cocaine-seeking behavior without causing reward.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olfactory dysfunction in patients with type 2 diabetes mellitus.

Rhinology·2024
Same author

Correction to: Cross-cultural adaptation and validation of the SNOT-22 into Italian.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2022
Same author

Insight into susceptibility genes associated with bipolar disorder: a systematic review.

European review for medical and pharmacological sciences·2021
Same author

Effect of surgery, delivery device and head position on sinus irrigant penetration in a cadaver model.

The Journal of laryngology and otology·2021
Same author

Multiple gene expression profiling suggests epithelial dysfunction in polypoid chronic rhinosinusitis.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale·2019
Same author

Frontal sinus ablation (Riedel-Mosher’s procedure): indications and role in the endonasal endoscopic era.

Rhinology·2019
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Research

Background:

  • Drug craving and relapse are significant challenges in addiction treatment.
  • Environmental cues associated with drug use can trigger intense cravings and relapse.
  • Dopamine D3 receptors play a crucial role in reward pathways and addiction.

Purpose of the Study:

  • To evaluate the efficacy of BP-897, a novel dopamine D3 receptor agonist, in preclinical models of drug craving and relapse.
  • To investigate the mechanism of action of BP-897 in modulating drug-seeking behavior.

Main Methods:

  • Preclinical studies in rats and mice, including behavioral assays for cocaine-seeking behavior.
  • In vitro and in vivo pharmacological characterization of BP-897 as a dopamine D3 receptor agonist.

Related Experiment Videos

  • Assessment of BP-897's effects in D3 receptor knockout mice and in non-human primates.

    • Main Results:

    • BP-897 demonstrated a dose-dependent reduction in cue-elicited cocaine-seeking behavior in rats.
    • The compound acts as a partial agonist in vitro and exhibits agonist or antagonist properties in vivo.
    • BP-897 did not produce intrinsic rewarding effects and had no impact on D3 receptor knockout mice or cocaine self-administration in monkeys.

    Conclusions:

    • BP-897 effectively inhibits drug-associated cue-induced cocaine-seeking behavior in preclinical models.
    • Its mechanism involves modulation of dopamine D3 receptor activity, suggesting therapeutic potential for addiction.
    • Further clinical investigation is warranted to confirm its efficacy and safety in humans for treating drug craving and relapse.